Skip to main content
. 2020 Jan 7;7(1):173–190. doi: 10.1007/s40744-019-00192-5

Fig. 1.

Fig. 1

Baseline levels (median, interquartile range) of biomarkers in DARWIN 1 (filgotinib on MTX background therapy) and DARWIN 2 (filgotinib monotherapy)